Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer

Giovanni Scambia, Domenica Lorusso, Alessia Di Legge, In Trivellizzi, Mc Moruzzi, Alessandra Pesce

Risultato della ricerca: Contributo in rivistaArticolo in rivista

20 Citazioni (Scopus)

Abstract

Advanced or recurrent endometrial cancer is associated with a poor prognosis, and results obtained with systemic therapy are far from being impressive. Myocet is an interesting formulation of citrate conjugated doxorubicin encapsulated in nonpegylated liposomes. This phase 2 study was designed to evaluate the objective response rate and the toxicity profile of Myocet in women with advanced or recurrent endometrial cancer.
Lingua originaleEnglish
pagine (da-a)1446-1451
Numero di pagine6
RivistaInternational Journal of Gynecological Cancer
Volume21
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Aged
  • Aged, 80 and over
  • Antibiotics, Antineoplastic
  • Carcinoma
  • Doxorubicin
  • Endometrial Neoplasms
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Treatment Failure

Fingerprint Entra nei temi di ricerca di 'Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer'. Insieme formano una fingerprint unica.

Cita questo